Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celsion Corp (CLSN)

Celsion Corp (CLSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,038
  • Shares Outstanding, K 22,756
  • Annual Sales, $ 500 K
  • Annual Income, $ -11,880 K
  • 60-Month Beta 1.98
  • Price/Sales 52.51
  • Price/Cash Flow N/A
  • Price/Book 1.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.25
  • Prior Year 0.32
  • Growth Rate Est. (year over year) -162.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.16 +9.48%
on 02/14/20
1.70 -25.29%
on 01/21/20
-0.38 (-22.84%)
since 01/17/20
3-Month
1.16 +9.48%
on 02/14/20
1.78 -28.65%
on 12/26/19
-0.18 (-12.41%)
since 11/19/19
52-Week
1.05 +20.95%
on 11/13/19
2.63 -51.71%
on 03/12/19
-0.91 (-41.74%)
since 02/19/19

Most Recent Stories

More News
Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m(2) in 15 Randomized Patients with Advanced Ovarian Cancer

Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy

CLSN : 1.27 (-3.79%)
Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox(R) Trial Data at SPECTRUM 2020 Interventional Oncology Conference

Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020

CLSN : 1.27 (-3.79%)
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.

ALXN : 103.21 (+1.03%)
CLSN : 1.27 (-3.79%)
AVXL : 5.34 (-8.09%)
ASLN : 2.14 (-0.47%)
Momenta (MNTA) Provides Pipeline Updates, Stock Rallies

Shares of Momenta (MNTA) rise 23.7% on pipeline updates.

ALXN : 103.21 (+1.03%)
MNTA : 33.79 (+2.92%)
CLSN : 1.27 (-3.79%)
ASLN : 2.14 (-0.47%)
Ultragenyx Provides Preliminary Crysvita 2019 Revenues

Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.

RARE : 61.55 (+0.74%)
CLSN : 1.27 (-3.79%)
ALXN : 103.21 (+1.03%)
ASLN : 2.14 (-0.47%)
Applied Therapeutics Up on Positive Galactosemia Study Data

Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.

EPZM : 25.18 (-0.28%)
AMRN : 18.10 (-0.49%)
CLSN : 1.27 (-3.79%)
APLT : 41.17 (-8.31%)
Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder

Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.

JNJ : 148.94 (-0.13%)
CLSN : 1.27 (-3.79%)
CHRS : 22.50 (+1.53%)
PTGX : 8.82 (+2.68%)
aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma

aTyr Pharma (LIFE) soars on a collaboration and license agreement with Kyorin Pharmaceutical for lead candidate.

LIFE : 4.21 (-0.24%)
EPZM : 25.18 (-0.28%)
AMRN : 18.10 (-0.49%)
CLSN : 1.27 (-3.79%)
Celsion's New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox(R) in China and Southeast Asia

-- Celsion's Chinese manufacturing partner, Hisun, to provide ThermoDox with an economically viable cost structure in China and other emerging markets.

CLSN : 1.27 (-3.79%)
Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program

Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share

CLSN : 1.27 (-3.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CLSN with:

Business Summary

Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the...

See More

Key Turning Points

2nd Resistance Point 1.35
1st Resistance Point 1.31
Last Price 1.27
1st Support Level 1.25
2nd Support Level 1.23

See More

52-Week High 2.63
Fibonacci 61.8% 2.03
Fibonacci 50% 1.84
Fibonacci 38.2% 1.65
Last Price 1.27
52-Week Low 1.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar